Repaglinide
16 NDCs across 6 manufacturers|16 Generic,0 Brand
Repaglinide is used to treat type 2 diabetes mellitus, per the National Library of Medicine's MED-RT classification.
▸ More about this market▾ Less
The brand product was first FDA-approved on Dec 22, 1997, and the first generic was approved Jul 11, 2013. FDA's Orange Book lists 9 AB-rated (therapeutically equivalent) products for this ingredient. In 2024, Medicare Part D spent $12 million on Repaglinide across 360,000 claims for 92,000 beneficiaries.
Repaglinide is available as 16 NDCs from 6 manufacturers (16 generic, 0 brand), with NADAC prices from $0.08 to $0.10 per EA — a 28% difference between cheapest and most expensive. Every pack size and labeler in this drug market is compared side-by-side below.
Total NDCs
16
16G / 0B
Manufacturers
6
competing in market
Price Spread
$0.08 – $0.10
per EA
7d Activity
avg +1.5% WoW · of 16 NDCs
Market Price Trend
Monthly average NADAC per unit, split by generic and brand.
Explore this market from other angles
Move from the molecule page into the supplier, class, and trend views that create the strongest internal-link cluster for this market.
Top supplier
Aurobindo Pharma Limited manufacturer profile
Open the supplier page for the manufacturer with the strongest footprint in this market.
Lead class
Glinide class view
See how this market rolls up into the broader therapeutic class and compare other drugs in the same bucket.
Trend hub
Latest market trends
Move from this single molecule into the current cross-market mover and volatility view.
Guide
How to interpret NADAC
Review the benchmark methodology behind the prices and spreads shown on this market page.
Manufacturer Breakdown
6 manufacturers producing REPAGLINIDE(1 pricing outlier)
| Drug ↕ | Price | 7d Change ↕ |
|---|---|---|
REPAGLINIDE 1 MG TABLET | $0.0987 per EA | +5.37% |
REPAGLINIDE 1 MG TABLET | $0.0987 per EA | +5.37% |
REPAGLINIDE 1 MG TABLET | $0.0987 per EA | +5.37% |
REPAGLINIDE 1 MG TABLET | $0.0987 per EA | +5.37% |
REPAGLINIDE 1 MG TABLET | $0.0987 per EA | +5.37% |
REPAGLINIDE 1 MG TABLET | $0.0987 per EA | +5.37% |
REPAGLINIDE 2 MG TABLET | $0.0925 per EA | -3.97% |
REPAGLINIDE 2 MG TABLET | $0.0925 per EA | -3.97% |
REPAGLINIDE 2 MG TABLET | $0.0925 per EA | -3.97% |
REPAGLINIDE 2 MG TABLET | $0.0925 per EA | -3.97% |
REPAGLINIDE 2 MG TABLET | $0.0925 per EA | -3.97% |
REPAGLINIDE 0.5 MG TABLET | $0.0772 per EA | +2.22% |
REPAGLINIDE 0.5 MG TABLET | $0.0772 per EA | +2.22% |
REPAGLINIDE 0.5 MG TABLET | $0.0772 per EA | +2.22% |
REPAGLINIDE 0.5 MG TABLET | $0.0772 per EA | +2.22% |
REPAGLINIDE 0.5 MG TABLET | $0.0772 per EA | +2.22% |
Frequently Asked Questions
What is Repaglinide used to treat?
Repaglinide is used to treat type 2 diabetes mellitus, per the National Library of Medicine's MED-RT classification.
When did Repaglinide become available as a generic?
FDA approved the first generic Repaglinide (ANDA) on Jul 11, 2013. The Orange Book currently lists 9 AB-rated products for this ingredient, meaning FDA considers them therapeutically equivalent to the brand.
How much does Medicare spend on Repaglinide?
In 2024, Medicare Part D spent $12 million on Repaglinide across 360,000 claims for 92,000 beneficiaries.
How many Repaglinide products are on the market?
The Repaglinide drug market contains 16 NDCs from 6 manufacturers — 16 generic and 0 brand products.
What is the price range for Repaglinide?
NADAC reference prices for Repaglinide range from $0.0772 to $0.0987 per EA — a 28% difference between cheapest and most expensive.
Which manufacturers make Repaglinide?
6 manufacturers list Repaglinide in NADAC. Ranked by number of NDCs, the largest are Aurobindo Pharma Limited (3), Chartwell RX LLC (3), NorthStar Rx LLC (3), Rising Pharma Holdings Inc. (3), Macleods Pharmaceuticals Limited (3).
How has the price of Repaglinide changed recently?
Over the past 7 days, 11 Repaglinide NDCs rose and 5 fell, with a market-wide average change of +1.5%.